Information Provided By: 
Fly News Breaks for December 13, 2018
NBIX
Dec 13, 2018 | 08:02 EDT
Baird analyst Brian Skorney removed Neurocrine's Fresh Pick designation and reduced his price target to $96 from $131 after the company announced that valbenazine did not meet its primary endpoint in a Phase 2b trial for pediatric Tourette syndrome. The analyst, who maintains an Outperform rating, reduced his peak sales estimate for Ingrezza to $1.17B from $2.09B to account for the removal of the Tourette market opportunity.
News For NBIX From the Last 2 Days
There are no results for your query NBIX
